Skip to main content
. 2019 Jul 18;17(6):883–893. doi: 10.1007/s40258-019-00496-1

Fig. 2.

Fig. 2

Relative effects of individual parameters in comparison with the base-case incremental cost-effectiveness ratio of £61,941/quality-adjusted life-year. Note that some parameters are only varied one way because the base case represents the maximum or minimum. acal acalabrutinib, AE adverse events, BSC best supportive care, C costs, ibru ibrutinib, OS overall survival, PFS progression-free survival, PPS post-progression survival, ST subsequent treatment, U utility